Thermo Fisher Scientific sells its microbiology business to European PE firm Astorg for $1.08 billion in life-sciences divestiture
Thermo Fisher Scientific, the US medical equipment and scientific instruments group, has agreed to sell its microbiology business to Astorg, a European private equity firm, for approximately $1.08 billion. The deal represents a clean disposal of a non-core division from one of the world's largest life-sciences companies, with Astorg acquiring a standalone business that operates in the diagnostics and microbiology testing segment. The transaction reflects a broader pattern of large-cap corporates rationalising their portfolios to focus capital and management attention on higher-growth core activities. For Thermo Fisher, the microbiology unit sits outside the company's primary focus on analytical instruments, reagents, consumables, and bioproduction services. A billion-dollar carve-out of this type typically involves significant complexity: separating shared infrastructure, IT systems, regulatory licences, and commercial contracts from the parent before transfer to a PE buyer. Astorg, which operates across European buyout markets with a focus on healthcare, software, and professional services, adds a specialised diagnostics asset to its portfolio. The deal structure and conditions precedent to closing were not detailed in the sources, but transactions of this scale in the EU and US will typically require merger control filings in multiple jurisdictions. No legal advisers are named in the available sources.
Why this matters
A $1.08 billion corporate carve-out activates several practice areas simultaneously: M&A (SPA negotiation and regulatory approvals), banking and finance (acquisition financing for the PE buyer), and employment (TUPE-equivalent transfer of workforce). The life-sciences sector has seen sustained divestiture activity as large-cap groups face investor pressure to simplify and improve return on capital. Astorg's acquisition of a regulated healthcare business in a multi-jurisdictional setting will require merger filings and likely healthcare regulatory consents alongside standard deal documentation. The carve-out structure is the most legally intensive variant of M&A — separating regulated assets from a parent requires bespoke transitional services agreements and IP licensing arrangements that generate substantial advisory mandates.
On the Ground
On this type of matter, a trainee would assist with due diligence report indexing — cataloguing regulatory licences, supply agreements, and real estate leases that need to be transferred or novated as part of the carve-out. They would also help maintain the conditions precedent (CP) checklist, tracking merger control filings and clearances across each relevant jurisdiction ahead of completion.
Interview prep
Soundbite
PE carve-outs of regulated healthcare assets generate the densest advisory work in M&A — multi-jurisdictional filings plus standalone infrastructure creation.
Question you might get
“What specific legal complexities arise in a corporate carve-out that would not appear in a straightforward share sale, and how would they affect deal timetable and cost?”
Full answer
Thermo Fisher has agreed to sell its microbiology business to European PE firm Astorg for $1.08 billion — a classic large-cap divestiture of a non-core division. For law firms, the commercial interest lies in the carve-out structure: separating a regulated healthcare business from a global parent requires bespoke transitional services agreements, IP licensing, and workforce transfer arrangements on top of standard M&A documentation. This reflects the wider trend of life-sciences corporates streamlining portfolios under investor pressure to improve capital allocation. A deal of this size will require merger control filings in multiple jurisdictions, adding regulatory advisory work to the corporate mandate. This suggests carve-out M&A in healthcare remains a consistent source of complex, high-fee work regardless of broader deal market conditions.
My notes
saved